skip to content
Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application Preview this item
ClosePreview this item
Checking...

Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application

Author: Paul D Rennert
Publisher: Switzerland : Springer, 2016.
Edition/Format:   eBook : Document : EnglishView all editions and formats
Summary:
Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Genre/Form: Electronic books
Additional Physical Format: Print version:
Rennert, Paul D.
Novel Immunotherapeutic Approaches to the Treatment of Cancer : Drug Development and Clinical Application
Cham : Springer International Publishing,c2016
Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Paul D Rennert
ISBN: 9783319298276 3319298275
OCLC Number: 950971534
Notes: Includes index.
Description: 1 online resource (xi, 276 pages) : color illustrations
Contents: Introduction --
Enhancing the efficacy of checkpoint blockade through combination therapies --
Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily --
Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 --
NK Cell Responses in Immunotherapy --
Reversing T cell dysfunction for tumor immunotherapy --
Immunomodulation within a single tumor site to induce systemic anti-tumor immunity --
Novel Targets and Their Assessment for Cancer Treatment --
The New Frontier of Antibody Drug Conjugates --
Cellular Therapies --
Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer.
Responsibility: Paul D. Rennert, editor.

Abstract:

Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers. .

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/950971534> # Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application
    a schema:Book, schema:MediaObject, schema:CreativeWork ;
    library:oclcnum "950971534" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/sz> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_evidence_based_medicine> ; # MEDICAL / Evidence-Based Medicine
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/neoplasms_therapy> ; # Neoplasms--therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/neoplasms_drug_therapy> ; # Neoplasms--drug therapy
    schema:about <http://dewey.info/class/616.99406/e23/> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/health_&_fitness_diseases_general> ; # HEALTH & FITNESS / Diseases / General
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_clinical_medicine> ; # MEDICAL / Clinical Medicine
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/cancer_immunotherapy> ; # Cancer--Immunotherapy
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_diseases> ; # MEDICAL / Diseases
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_internal_medicine> ; # MEDICAL / Internal Medicine
    schema:about <http://experiment.worldcat.org/entity/work/data/2888864932#Topic/immunotherapy> ; # Immunotherapy
    schema:bookFormat schema:EBook ;
    schema:datePublished "2016" ;
    schema:description "Cancer care is undergoing a radical transformation as novel technologies are directed toward new treatments and personalized medicine. The most dramatic advances in the treatment of cancer have come from therapeutics that augment the immune response to tumors. The immune checkpoint inhibitors are the best-known and most highly advanced examples of Immune Therapeutics targeting tumor cells and include approved antibody drugs directed at the cell surface proteins CTLA4 and PD-1. These are now considered foundational treatments for several solid tumor indications, and that list of indications is growing quickly. More broadly, antibodies have become workhorse molecules across the entire immunotherapy landscape. Antibodies to novel targets modulate the activity of diverse immune cell regulatory proteins. Engineered antibodies can induce tumor cell death or expose tumor cells to poisonous toxins (ADCC and ADC, respectively). Bi-specific antibodies can engage multiple tumor targets simultaneously, or can redirect lymphocytes to attack tumor cells. The antigen-binding domains within antibodies can be spliced onto cell stimulatory domains and transduced into T cells or NK cells, creating remarkable tumor-specific cellular therapeutics (CAR-T, CAR-NK). Beyond antibody-based therapies there are highly diverse and differentiated technology tool kits being applied to immunotherapy. Small molecule drugs are being developed to attack the tumor microenvironment, novel tumor vaccine approaches are showing great promise, patient lymphocytes are being isolated, expanded and reintroduced to patients, gene-editing techniques are becoming widely deployed, and a vast number of new tumor targets, and mutated tumor proteins (neoantigens), are being discovered. The past decade has seen unprecedented success in the treatment of diverse cancers. The authors of this volume have been asked to not only review progress to date, but importantly, to look ahead, and anticipate the evolution of cancer treatment across diverse Immune Therapeutic approaches. Our hypothesis is that the advances we are seeing across the immunotherapy landscape will further evolve and synergize, leading us finally to outright cures for many cancers. ."@en ;
    schema:description "Introduction -- Enhancing the efficacy of checkpoint blockade through combination therapies -- Novel Immunomodulatory Targets in the Immunoglobulin-Superfamily -- Parallel Costimulation of Effector and Regulatory T Cells by OX40, GITR, TNFRSF25, CD27 and CD137 -- NK Cell Responses in Immunotherapy -- Reversing T cell dysfunction for tumor immunotherapy -- Immunomodulation within a single tumor site to induce systemic anti-tumor immunity -- Novel Targets and Their Assessment for Cancer Treatment -- The New Frontier of Antibody Drug Conjugates -- Cellular Therapies -- Targeting the Physicochemical, Cellular, and Immunosuppressive Properties of the Tumor Microenvironment by Depletion of Hyaluronan to Treat Cancer."@en ;
    schema:editor <http://experiment.worldcat.org/entity/work/data/2888864932#Person/rennert_paul_d> ; # Paul D. Rennert
    schema:exampleOfWork <http://worldcat.org/entity/work/id/2888864932> ;
    schema:genre "Electronic books"@en ;
    schema:inLanguage "en" ;
    schema:isSimilarTo <http://worldcat.org/entity/work/data/2888864932#CreativeWork/novel_immunotherapeutic_approaches_to_the_treatment_of_cancer_drug_development_and_clinical_application> ;
    schema:name "Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application"@en ;
    schema:productID "950971534" ;
    schema:url <http://libproxy.uwyo.edu/login/?url=http://dx.doi.org/10.1007/978-3-319-29827-6> ;
    schema:url <https://login.libproxy.noctrl.edu/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <http://er.llcc.edu:2048/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <http://sfx.carli.illinois.edu/sfxwhe/sfx_local?genre=book&sid=Voyager:WHE&sfx.ignore_date_threshold=1&svc.fulltext=yes&rft.isbn=978-3-319-29827-6> ;
    schema:url <http://dx.doi.org/10.1007/978-3-319-29827-6> ;
    schema:url <https://login.proxy.lib.strath.ac.uk/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <http://link.springer.com/openurl?genre=book&isbn=978-3-319-29825-2> ;
    schema:url <https://0-link-springer-com.pugwash.lib.warwick.ac.uk/book/10.1007/978-3-319-29827-6> ;
    schema:url <http://public.eblib.com/choice/PublicFullRecord.aspx?p=4534017> ;
    schema:url <https://link.springer.com/openurl?genre=book&isbn=978-3-319-29825-2> ;
    schema:url <https://proxy1.library.eiu.edu/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <http://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=1175964> ;
    schema:url <http://lib.myilibrary.com?id=928333> ;
    schema:url <https://login.libproxy.uregina.ca:8443/login?url=http://link.springer.com/openurl?genre=book&isbn=978-3-319-29825-2> ;
    schema:url <http://libproxy.uwinnipeg.ca/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <https://grinnell.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <https://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:url <http://proxy.artic.edu/login?url=http://link.springer.com/10.1007/978-3-319-29827-6> ;
    schema:workExample <http://worldcat.org/isbn/9783319298276> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/950971534> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/2888864932#Person/rennert_paul_d> # Paul D. Rennert
    a schema:Person ;
    schema:familyName "Rennert" ;
    schema:givenName "Paul D." ;
    schema:name "Paul D. Rennert" ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/cancer_immunotherapy> # Cancer--Immunotherapy
    a schema:Intangible ;
    schema:name "Cancer--Immunotherapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/health_&_fitness_diseases_general> # HEALTH & FITNESS / Diseases / General
    a schema:Intangible ;
    schema:name "HEALTH & FITNESS / Diseases / General"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_clinical_medicine> # MEDICAL / Clinical Medicine
    a schema:Intangible ;
    schema:name "MEDICAL / Clinical Medicine"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_diseases> # MEDICAL / Diseases
    a schema:Intangible ;
    schema:name "MEDICAL / Diseases"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_evidence_based_medicine> # MEDICAL / Evidence-Based Medicine
    a schema:Intangible ;
    schema:name "MEDICAL / Evidence-Based Medicine"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/medical_internal_medicine> # MEDICAL / Internal Medicine
    a schema:Intangible ;
    schema:name "MEDICAL / Internal Medicine"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/neoplasms_drug_therapy> # Neoplasms--drug therapy
    a schema:Intangible ;
    schema:name "Neoplasms--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/2888864932#Topic/neoplasms_therapy> # Neoplasms--therapy
    a schema:Intangible ;
    schema:name "Neoplasms--therapy"@en ;
    .

<http://lib.myilibrary.com?id=928333>
    rdfs:comment "Connect to MyiLibrary resource." ;
    .

<http://worldcat.org/entity/work/data/2888864932#CreativeWork/novel_immunotherapeutic_approaches_to_the_treatment_of_cancer_drug_development_and_clinical_application>
    a schema:CreativeWork ;
    rdfs:label "Novel Immunotherapeutic Approaches to the Treatment of Cancer : Drug Development and Clinical Application" ;
    schema:description "Print version:" ;
    schema:isSimilarTo <http://www.worldcat.org/oclc/950971534> ; # Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application
    .

<http://worldcat.org/isbn/9783319298276>
    a schema:ProductModel ;
    schema:isbn "3319298275" ;
    schema:isbn "9783319298276" ;
    .

<http://www.worldcat.org/title/-/oclc/950971534>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/950971534> ; # Novel immunotherapeutic approaches to the treatment of cancer : drug development and clinical application
    schema:dateModified "2018-12-13" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .

<https://login.libproxy.uregina.ca:8443/login?url=http://link.springer.com/openurl?genre=book&isbn=978-3-319-29825-2>
    rdfs:comment "Full text available from SpringerLINK ebooks - Biomedical and Life Sciences (2016)" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.